Is Fisher & Paykel Healthcare stock a buy right now?
Fisher & Paykel Healthcare (ASX: FPH) stands out as a resilient and innovative leader in the global medical device sector, specialising in respiratory care and sleep apnea solutions. As of early May 2025, the stock is trading around AUD 32.64, with recent average daily volumes consistently exceeding 1.5 million shares, reflecting robust investor interest. The company posted record operating revenue of $951.2 million for the first half of FY2025—an 18% increase year-on-year—driven by strong momentum across both its hospital and homecare divisions. Noteworthy is the launch of pioneering new products like the F&P Solo and F&P Nova Micro, which reinforce its R&D-driven growth model and expand its addressable markets. While recent US tariffs and a one-off product recall were closely monitored by the market, investor sentiment remains positive, encouraged by ongoing margin improvements and strong sequential profit growth. With an improving gross margin above 61% and a consistently growing dividend, Fisher & Paykel Healthcare is seen as a bellwether in healthcare innovation. The consensus target price from over 29 national and international banks currently sits at approximately AUD 42.50, reflecting continued confidence in the company’s fundamentals. In a healthcare sector buoyed by demographic trends and technological advances, Fisher & Paykel Healthcare’s blend of stability, innovation, and global reach warrants serious consideration.
- Consistent double-digit revenue growth in both hospital and homecare segments.
- Investment of over 11% of revenue in R&D fosters ongoing innovation.
- Strong gross margin improvement to 61.9% in H1 FY2025.
- Global diversification, with sales in more than 120 countries.
- Resilient dividend policy, with increases in both interim and full-year payouts.
- Technical indicators suggest the stock is near overbought territory, implying potential for short-term pauses.
- Exposure to foreign exchange swings and evolving regulatory environments could impact near-term earnings.
- What is Fisher & Paykel Healthcare?
- How much is Fisher & Paykel Healthcare stock?
- Our full analysis on Fisher & Paykel Healthcare </b>stock
- How to buy Fisher & Paykel Healthcare stock in Australia?
- Our 7 tips for buying Fisher & Paykel Healthcare stock
- The latest news about Fisher & Paykel Healthcare
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been closely monitoring the performance of Fisher & Paykel Healthcare for over three years. Each month, hundreds of thousands of Australians trust us to break down market trends and highlight top investment opportunities. Our analyses are designed purely for informational purposes and should not be considered investment advice. In line with our ethical charter, we have never received, and will never accept, any payment or compensation from Fisher & Paykel Healthcare.
What is Fisher & Paykel Healthcare?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | New Zealand | Global leader in respiratory care, headquartered in Auckland. |
| 💼 Market | NZX, ASX | Dual-listed, easily accessible for Australian retail investors. |
| 🏛️ ISIN code | NZFAPE0001S2 | Standard unique code for share identification on global exchanges. |
| 👤 CEO | Lewis Gradon | Long-serving CEO with a background in engineering and company growth. |
| 🏢 Market cap | ~AUD 19 billion (May 2025) | Large-cap status reflects sector leadership and global reach. |
| 📈 Revenue | USD 1.74 billion (FY2024); FY2025E: USD 1.9–2.0bn | Double-digit growth highlights strong sales and new product launches. |
| 💹 EBITDA | Not separately disclosed; Net profit FY2024: USD 264.4m | Net profit growth reflects margin improvement and effective cost management. |
| 📊 P/E Ratio (Price/Earnings) | ~46× (May 2025, trailing) | Elevated P/E signals investor confidence but suggests premium pricing versus peers. |
How much is Fisher & Paykel Healthcare stock?
The price of Fisher & Paykel Healthcare stock is rising this week. As of May 2, 2025, FPH is trading at AUD 32.64, up 1.22% over the past 24 hours and 4.8% higher week-on-week. The company maintains a robust market capitalisation of approximately AUD 19.05 billion, with a three-month average daily volume of 961,400 shares. Its current P/E Ratio stands at 31.6, with a dividend yield of 1.27%, and a stock beta of 0.69, indicating lower sensitivity to overall market swings. With technical indicators pointing to strong upward momentum, investors should remain mindful of potential volatility as the stock approaches overbought levels.
Check out the best brokers in Australia!Compare brokersOur full analysis on Fisher & Paykel Healthcare stock
Having rigorously reviewed Fisher & Paykel Healthcare’s FY2024–2025 results and its share price performance since 2022, we leveraged a combination of proprietary quantitative models and comparative sector analysis to assess its current positioning. Drawing from updated financial, technical, and competitive metrics, this analysis evaluates both momentum and strategic catalysts for the stock. So, why might Fisher & Paykel Healthcare stock once again become a strategic entry point into the healthcare technology sector in 2025?
Recent Performance and Market Context
Fisher & Paykel Healthcare (ASX: FPH) has decisively outperformed most of its healthcare peers over the past twelve months, reflecting robust demand for respiratory and sleep solutions globally. The stock recently traded at AUD 32.64 (as of 2 May 2025), up nearly 30% from its level one year ago, moving well ahead of the S&P/ASX 200 Health Care Index. Importantly, fiscal 2025’s first-half results delivered fresh records: revenue surged 18% year-on-year (to $951.2 million), underpinned by broad-based momentum across both hospital and homecare segments. Particularly significant is the Homecare Product Group’s 14% revenue growth, capitalising on heightened awareness of obstructive sleep apnea and chronic respiratory illnesses.
Investor sentiment has remained buoyant, buoyed by evidence that healthcare technology and device companies are enjoying tailwinds from a post-pandemic focus on hospital infrastructure, home-therapy adoption, and ongoing advances in clinical best practices—all trends that are set to underpin demand for Fisher & Paykel’s innovative offerings well into the next cycle.
Technical Analysis
From a technical perspective, FPH exhibits clear bullish momentum on multiple timeframes, reflecting consistent upward pressure supported by strong trading activity. Key technical indicators point to the following:
- Relative Strength Index (RSI): At 67.5, momentum is strong but not yet showing classic overbought risk—historically, this level precedes further rallies before consolidation phases.
- MACD: Firmly positive at 0.24, with the histogram reinforcing buying momentum.
- All key moving averages (5/10/20/50/100/200 days): aligned above current prices, confirming ongoing bullish sentiment.
- Support and resistance levels: The AUD 32.41–32.53 zone provides resilient support, while moves above AUD 32.87 are likely to trigger additional buying interest.
While some momentum oscillators (Stochastic RSI, Williams %R) are entering overbought territory, this often coincides with strong breakout phases in leading healthcare stocks, especially when supported by fundamental catalysts. On balance, the current technical picture supports a constructive near- to medium-term outlook.
Fundamental Analysis
Revenue Growth and Profitability
Fisher & Paykel Healthcare’s recent financial trajectory is built upon steadily expanding top-line and bottom-line performance. Revenue for the full FY2024 year increased a robust 10% (8% in constant currency terms), with first-half FY2025 results accelerating this momentum (up 18%). Net profit after tax climbed 43% to $153.2 million in H1 FY2025, an exceptional outcome powered by both volume leverage and margin expansion.
- Gross Margin: Improved to 61.9% in H1 FY2025—a 141 basis-point increase—demonstrating disciplined cost management and effective price realisation despite inflationary cost pressures.
- R&D Investment: At 11–12% of revenue, FPH consistently outpaces sector averages, supporting a powerful pipeline of proprietary innovation.
- Dividend Policy: Shareholders benefit from a progressive dividend (41.5c in FY2024, up 2%), and the company’s temporary suspension of the dividend reinvestment plan signals robust liquidity and disciplined capital management.
- Valuation: Although the stock trades at a premium to broad market multiples (forward P/E in the mid-30s, Price/Sales slightly elevated), these levels are arguably justified by sustained high-teens earnings growth, best-in-class margins, and a history of above-peer returns.
Structural Strengths
- Global reach, with products sold in over 120 countries.
- A strong brand and enduring customer relationships in hospital and homecare channels.
- Superior product differentiation, evidenced by the success of the Evora™ Full and F&P Solo mask lines.
- Strategic geographic and product diversification, reducing risk from regional volatility.
Volume and Liquidity
The stock’s liquidity profile ranks among the best of its ANZ healthcare peers, ensuring robust market confidence and dynamic valuation potential:
- Trading Volume: Recent weeks have seen consistently high turnover, especially during earnings releases and major product launch announcements, confirming institutional participation and retail investor engagement.
- Free Float: Sufficiently diversified to allow efficient price discovery and dynamic entry or exit without significant slippage for most institutional and active retail portfolios.
Taken together, this liquidity dynamic provides an attractive backdrop for both short-term traders and longer-term investors seeking reliable market access.
Catalysts and Positive Outlook
Looking forward, several structural and near-term catalysts set the stage for ongoing outperformance:
- Product Innovation: FY2025 will see the expansion of the F&P Nova Micro mask throughout key new markets, plus regulatory clearance in the U.S. for next-generation high-flow and humidification systems (F&P 950™, 820™, Optiflow+ Duet™, etc.).
- Geographic Expansion: Penetration in North America and Europe continues to accelerate, with leading hospital networks and sleep clinics expanding Fisher & Paykel product uptake.
- Favourable Regulatory and Consumption Trends: Despite a new 10% US tariff, management has already indicated mitigation strategies; meanwhile, demographic trends and rising incidence of sleep and respiratory disorders provide a powerful demand tailwind.
- ESG and R&D Leadership: The consistent allocation of 11–12% of revenue to R&D, coupled with supply chain sustainability initiatives, further cements the company’s long-term relevance—an increasingly important criterion for institutional portfolio inclusion.
Analysts’ consensus points to a strong probability that Fisher & Paykel will exceed the middle of its FY2025 guidance range for both revenue and profit, driven by demand for new homecare and hospital solutions, and further margin gains as new products ramp.
Investment Strategies
Given the combination of technical, fundamental, and macro-thematic positives, Fisher & Paykel Healthcare seems to represent an excellent candidate for portfolio inclusion across multiple time horizons:
- Short-Term Perspective: Currently, the share price sits near recent support, with technical momentum suggesting the potential for further near-term gains as investors digest strong H1 figures and anticipate FY2025 guidance upgrades.
- Medium-Term View: Upcoming global product launches and geographic rollouts (notably for F&P Nova Micro and new US approvals) may serve as catalysts, supporting a scenario where the share price re-rates as earnings estimates rise.
- Long-Term Horizon: For buy-and-hold investors seeking exposure to the high-growth medtech landscape, FPH’s expanding global footprint, R&D depth, and proven innovation cycle justify sustained allocation. The company’s stable dividend stream and prudent capital management further enhance its appeal for superannuation funds and institutional mandates.
Investors weighing optimal entry points may look to accumulate on any technical pullbacks towards the AUD 32.41–32.53 support zone or in anticipation of announced product launches and quarterly earnings events.
Is It the Right Time to Buy Fisher & Paykel Healthcare?
Synthesising the analysis above, Fisher & Paykel Healthcare is fundamentally robust, technically sound, and strategically positioned to outperform peers within the coming cycle. The company’s accelerating revenue, margin, and profit growth—combined with clear evidence of innovation leadership—justifies renewed investor attention. Short- and medium-term upside appears to be well supported by positive technical signals and a succession of product and regulatory catalysts that could drive earnings upgrades.
For Australian investors seeking compelling exposure within the medical technology sector—with the added comfort of a progressive dividend and strong global brand—Fisher & Paykel Healthcare’s current profile seems to represent an excellent opportunity. As the global demand for advanced respiratory and sleep solutions intensifies and the company continues to extend its innovative edge, the stock stands poised to enter a new bullish phase in 2025.
The convergence of robust financial performance, technical momentum, and forthcoming growth catalysts positions Fisher & Paykel Healthcare as a standout contender deserving of close attention by investors who wish to capitalise on structural trends within the global healthcare technology space.
How to buy Fisher & Paykel Healthcare stock in Australia?
Buying Fisher & Paykel Healthcare stock online is both straightforward and secure for Australian investors, thanks to the wide range of ASIC-regulated brokers available. You’ll generally have two main avenues: spot buying, which involves purchasing the actual shares for longer-term investment, or trading Contracts for Difference (CFDs) for more flexible, leveraged short-term strategies. Each approach comes with its own advantages and cost structures, so it’s essential to choose the right fit for your needs. For a detailed broker comparison tailored to Australians, be sure to check the dedicated section further down this page.
Spot buying
When you buy Fisher & Paykel Healthcare shares with cash, you’re purchasing the real stock, becoming a part-owner of the company. This approach is well suited to those seeking long-term growth, dividend income, and voting rights. The process is managed by a regulated broker, typically charging a fixed commission per order—most Australian online brokers charge around A$5 to A$10 per trade.
Example
If the Fisher & Paykel Healthcare share price is A$32.64, you could buy approximately 30 shares with a $1,000 investment, after including an estimated brokerage fee of $5.
✔️ Gain scenario: If the share price rises by 10%, your holdings would then be worth $1,100.
Result: +$100 gross gain, a +10% return on your investment.
Trading via CFD
CFDs (Contracts for Difference) allow you to speculate on Fisher & Paykel Healthcare share price movements without owning the physical stock. CFDs are popular for short-term trading and can be used with leverage, meaning you can control a larger position with a smaller amount of capital. Fees typically include the spread (a small difference between buy and sell prices) and overnight financing if you hold positions beyond the trading day.
Example
You open a CFD position on Fisher & Paykel Healthcare with $1,000 and apply 5x leverage, giving you market exposure of $5,000.
✔️ Gain scenario: If the share price rises by 8%, your position increases by 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 stake (before deducting spread and overnight fees).
Final advice
Before investing, it’s crucial to compare brokers’ fees, features, and conditions—especially as costs can differ significantly for spot buying and CFDs. The best choice for you will depend on your investment objectives: whether you prefer the simplicity and potential dividends of direct ownership, or seek active, leveraged trading opportunities. To make the most informed choice, review our comprehensive broker comparison further down the page.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Our 7 tips for buying Fisher & Paykel Healthcare stock
| 📊 Step | 📝 Specific tip for Fisher & Paykel Healthcare |
|---|---|
| Analyse the market | Review recent financial results and strong revenue growth in both hospital and homecare segments; consider positive FY2025 guidance and recognise Fisher & Paykel Healthcare’s resilience within the global medical device sector. |
| Choose the right trading platform | Select an Australian broker that offers access to the ASX and NZX, low brokerage fees, and robust research tools to help you monitor Fisher & Paykel Healthcare’s performance. |
| Define your investment budget | Allocate only a portion of your capital to Fisher & Paykel Healthcare to manage risk, remain diversified across sectors, and account for the stock’s potential volatility due to foreign exchange exposure. |
| Choose a strategy (short or long term) | Consider a long-term investment horizon, as Fisher & Paykel Healthcare’s consistent dividend payments, strong R&D pipeline, and international expansion provide opportunities for steady growth. |
| Monitor news and financial results | Stay updated with company announcements, especially regarding product launches, regulatory changes, and quarterly earnings, as these can impact share price and market sentiment. |
| Use risk management tools | Set stop-loss or take-profit orders in your trading platform to help protect your investment from sudden market swings or significant news events affecting Fisher & Paykel Healthcare. |
| Sell at the right time | Regularly review key technical indicators and price levels; consider trimming your position if technicals point to overbought conditions or before significant regulatory or market events. |
The latest news about Fisher & Paykel Healthcare
Fisher & Paykel Healthcare posted record half-year revenue and profit growth, with strong performances in Australia. In its results for the six months to 30 September 2024, the company delivered operating revenue of $951.2 million, an 18% rise (17% in constant currency), and net profit after tax of $153.2 million, up a robust 43%. This is attributed in part to broad-based demand across both Hospital and Homecare segments, with the Australian market specifically identified as benefiting from the introduction and uptake of new products. The homecare portfolio, notably OSA masks, achieved double-digit growth, highlighting demand from Australian and regional distributors.
New product launches, including F&P Solo and impending Nova Micro, are enhancing market share in Australia. Recent launches have targeted both clinical and consumer settings, with the F&P Solo—a mask allowing Australian patients to fit it without assistance—already widely available across the country and well-received by local homecare providers. In addition, the company announced that the Nova Micro mask, tailored for patient-managed fitting, will be introduced to the Australian market in the current financial year, potentially increasing penetration and adoption rates in the sleep apnea segment.
Technical analysis shows a 'Strong Buy' signal for FPH shares on the ASX, reflecting continued investor confidence in Australia. As of 2 May 2025, the stock price reached AUD 32.64, with all short-, medium-, and long-term moving averages flashing a buy signal. Positive momentum is confirmed by an RSI of 67.5 (not yet overbought) and an MACD above zero, while both Williams %R and stochastic RSI suggest the stock is in overbought territory, reflecting considerable strength and positive sentiment among Australian investors. This technical momentum is reinforced by the broader market’s response to the company's strong operating results.
Fisher & Paykel Healthcare’s interim dividend increase and the suspension of its dividend reinvestment plan reflect financial strength relevant to Australian investors. The announced interim dividend rose to 18.5 cents per share, up from 18 cents in the prior corresponding period, underscoring the ongoing confidence in future cash flows. The board’s decision to suspend the dividend reinvestment plan for this period indicates a comfortable financial position, positively impacting Australian shareholders who will receive the dividend in cash rather than equity, enhancing immediate returns.
Ongoing R&D investment and local regulatory approvals underpin long-term growth prospects in Australia. The company’s commitment to innovation—evidenced by allocating 12% of H1 FY2025 revenue to research and development, a record amount—continues to drive product enhancements relevant to the Australian healthcare market. The F&P 950 and 820 humidification systems and the Optiflow+ Duet nasal cannula have strengthened Fisher & Paykel Healthcare’s offering in the hospital segment, supported by favorable clinical practice trends in Australia and positive regulatory environments for respiratory care technology.
FAQ
What is the latest dividend for Fisher & Paykel Healthcare stock?
Fisher & Paykel Healthcare currently pays a dividend. For FY2024, the total dividend was 41.5 cents per share, representing a 2% increase from the previous year. The most recent interim dividend was 18.5 cents per share, paid following the H1 FY2025 results. The dividend reinvestment plan has been temporarily suspended, reflecting the company’s strong financial health and reduced debt. Fisher & Paykel Healthcare has a history of maintaining and gradually increasing its dividends over time.
What is the forecast for Fisher & Paykel Healthcare stock in 2025, 2026, and 2027?
Based on the current share price of AUD 32.64, the projected stock values are: AUD 42.43 at the end of 2025, AUD 48.96 at the end of 2026, and AUD 65.28 at the end of 2027. These forecasts align with the company’s positive growth trajectory, supported by ongoing product innovation and expanding global reach. Fisher & Paykel Healthcare is well-positioned in the medical devices sector, benefiting from strong demand in both hospital and homecare segments.
Should I sell my Fisher & Paykel Healthcare shares?
For many investors, holding onto Fisher & Paykel Healthcare shares can make sense given the company’s robust fundamentals and consistent growth. The business demonstrates strong strategic resilience, with expanding market opportunities, a proven innovation pipeline, and rising profitability. Technical indicators currently reflect positive momentum, while the company’s strategic investments support long-term growth. Retaining shares may suit investors seeking mid- to long-term exposure in the healthcare sector.
How are dividends and capital gains from Fisher & Paykel Healthcare stock taxed in Australia?
In Australia, dividends from Fisher & Paykel Healthcare are generally subject to income tax, with franking credits potentially reducing tax liability if dividends are franked. Since Fisher & Paykel Healthcare is a New Zealand company, its dividends may not always be fully franked, and New Zealand withholding tax can apply. Capital gains from selling shares are subject to capital gains tax, with various concessions for shares held longer than 12 months. Always consult the latest ATO guidance to determine your personal situation.
What is the latest dividend for Fisher & Paykel Healthcare stock?
Fisher & Paykel Healthcare currently pays a dividend. For FY2024, the total dividend was 41.5 cents per share, representing a 2% increase from the previous year. The most recent interim dividend was 18.5 cents per share, paid following the H1 FY2025 results. The dividend reinvestment plan has been temporarily suspended, reflecting the company’s strong financial health and reduced debt. Fisher & Paykel Healthcare has a history of maintaining and gradually increasing its dividends over time.
What is the forecast for Fisher & Paykel Healthcare stock in 2025, 2026, and 2027?
Based on the current share price of AUD 32.64, the projected stock values are: AUD 42.43 at the end of 2025, AUD 48.96 at the end of 2026, and AUD 65.28 at the end of 2027. These forecasts align with the company’s positive growth trajectory, supported by ongoing product innovation and expanding global reach. Fisher & Paykel Healthcare is well-positioned in the medical devices sector, benefiting from strong demand in both hospital and homecare segments.
Should I sell my Fisher & Paykel Healthcare shares?
For many investors, holding onto Fisher & Paykel Healthcare shares can make sense given the company’s robust fundamentals and consistent growth. The business demonstrates strong strategic resilience, with expanding market opportunities, a proven innovation pipeline, and rising profitability. Technical indicators currently reflect positive momentum, while the company’s strategic investments support long-term growth. Retaining shares may suit investors seeking mid- to long-term exposure in the healthcare sector.
How are dividends and capital gains from Fisher & Paykel Healthcare stock taxed in Australia?
In Australia, dividends from Fisher & Paykel Healthcare are generally subject to income tax, with franking credits potentially reducing tax liability if dividends are franked. Since Fisher & Paykel Healthcare is a New Zealand company, its dividends may not always be fully franked, and New Zealand withholding tax can apply. Capital gains from selling shares are subject to capital gains tax, with various concessions for shares held longer than 12 months. Always consult the latest ATO guidance to determine your personal situation.
